| Ytd | 171.50% | |
| 1y | 503.33% |
| Open | 10.55 | Prev Close | 10.71 | Low | 10.28 | High | 11.00 | Mkt Cap | 623.76M |
| Vol | 1.15M | Avg Vol | 1.37M | EPS | -0.82 | P/E | N/A | Forward P/E | -16.92 |
| Beta | -0.04 | Short Ratio | 5.77 | Inst. Own | 105.23% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-13 | 50-d Avg | 13.93 | 200-d Avg | 9.91 | 1yr Est | 22.86 |
CLYM News
Climb Bio offers investors exposure to two key immunology assets: CLYM116 for IgA nephropathy and bu
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for pa
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropat
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raise
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings larg
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy a
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and rais
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the pri
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA n
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy a
Truist Securities analyst Danielle Brill maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.18) per share which beat the analyst consen
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the pr
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Climb Bio (NASDAQ:CLYM) with a Buy
Up to $100,000,000Common StockWe have entered into an Open Market Sale AgreementSM, or the Sales Ag
Climb Bio (CLYM) shares positive Phase 1b data for budoprutug in ITP, showing robust B-cell depletio
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for pa
U.S. stocks higher, Nasdaq Composite up 1%. Tango Therapeutics (TNGX) shares up 34.1% on positive tr
Guggenheim analyst Yatin Suneja initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy rating a
The Company also announced that it plans to share initial pharmacokinetic and pharmacodynamic (PK/PD
Company to share additional CLYM116 clinical data and plans for further development at R&D Spotl
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy a
Wedbush analyst Laura Chico maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the pr
Climb Bio (NASDAQ:CLYM) reported quarterly losses of $(0.20) per share which beat the analyst consen
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price ta
Chardan Capital analyst Geulah Livshits initiates coverage on Climb Bio (NASDAQ:CLYM) with a Buy
Wall Street analysts have changed their outlook on top names, with new coverage and price targets. S
William Blair assigns Climb Bio an Outperform rating, projecting peak sales of $1.9 billion and long